BI 2536

Name: BI 2536
Brand: Selleck Chemicals
SKU: S1109
Rating: 5 (156 reviews)

For research use only.

Catalog No.S1109

156 publications

Molecular Weight(MW): 521.66

BI2536 is a potent Plk1 inhibitor with IC50 of 0.83 nM in a cell-free assay. It shows 4- and 11-fold greater selectivity against Plk2 and Plk3. Phase 2.

Selleck's BI 2536 has been cited by 156 publications

Cancer Cell, 2020, 37(3):340-353

PubMed: 32109375 ( click the link to review the publication )

Science, 2019, 364(6447)

PubMed: 31249032 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Nature, 2017, 548(7668):466-470

PubMed: 28759889 ( click the link to review the publication )

Cancer Discov, 2014, 4(11):1281-9

PubMed: 25107667 ( click the link to review the publication )

Cell, 2011, 4(10):1087-96

PubMed: 22078882 ( click the link to review the publication )

Cancer Cell, 2010, 18(6):641-54

PubMed: 21156286 ( click the link to review the publication )

Mol Cell, 2020, 10.1016/j.molcel.2020.01.023

PubMed: 32035037 ( click the link to review the publication )

Nat Commun, 2020, 29;11(1):2086

PubMed: 32350249 ( click the link to review the publication )

Nat Commun, 2020, 14;11(1):1819

PubMed: 32286328 ( click the link to review the publication )

Oncogene, 2020, 39(15):3145-3162

PubMed: 32060423 ( click the link to review the publication )

Cell Chem Biol, 2020, 27(3):350-362

PubMed: 32017920 ( click the link to review the publication )

ACS Chem Biol, 2020, 20;15(3):669-674

PubMed: 32004428 ( click the link to review the publication )

Biochem Biophys Res Commun, 2020, 521(4):833-839

PubMed: 31708096 ( click the link to review the publication )

DNA Cell Biol, 2020, 10.1089/dna.2019.5002

PubMed: 32182129 ( click the link to review the publication )

Cell Death Differ, 2020, 10.1038

PubMed: 32015503 ( click the link to review the publication )

Cells, 2020, 9(1)

PubMed: 31947732 ( click the link to review the publication )

J Cancer, 2020, 11(11):3274-3287

PubMed: 32231733 ( click the link to review the publication )

Cell Res, 2019, 29(7):562-578

PubMed: 31201382 ( click the link to review the publication )

Mol Cell, 2019, 73(5):915-929

PubMed: 30849395 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3779

PubMed: 31439829 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1473

PubMed: 30931927 ( click the link to review the publication )

Nat Commun, 2019, 10(1):993

PubMed: 30824690 ( click the link to review the publication )
Sci Adv, 2019, 5(8):eaav0318

PubMed: 31803841 ( click the link to review the publication )

Cell Syst, 2019, 8(2):163-167

PubMed: 30797774 ( click the link to review the publication )

Cell Syst, 2019, 9(1):74-92.e8

PubMed: 31302152 ( click the link to review the publication )

EBioMedicine, 2019, 41:244-255

PubMed: 30876762 ( click the link to review the publication )

Cell Death Dis, 2019, 10(6):385

PubMed: 31097686 ( click the link to review the publication )

Ther Adv Med Oncol, 2019, 11:1758835919846375

PubMed: 31156720 ( click the link to review the publication )

J Mol Cell Biol, 2019, 10.1093/jmcb/mjz051

PubMed: 31174204 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(9):1615-1627

PubMed: 31227645 ( click the link to review the publication )

FEBS J, 2019, 286(5):963-974

PubMed: 30600590 ( click the link to review the publication )

Mol Cancer Res, 2019, doi: 10

PubMed: 31604847 ( click the link to review the publication )

Lab Invest, 2019, 99(9):1275-1286

PubMed: 30996295 ( click the link to review the publication )

Open Biol, 2019, 9(8):190136

PubMed: 31455158 ( click the link to review the publication )

Mol Cell, 2018, 71(1):117-128

PubMed: 30008317 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(9)

PubMed: 30108112 ( click the link to review the publication )

Theranostics, 2018, 8(10):2884-2895

PubMed: 29774081 ( click the link to review the publication )

Cancer Res, 2018, 78(2):572-583

PubMed: 29180474 ( click the link to review the publication )

Sci Signal, 2018, 11(549)

PubMed: 30254057 ( click the link to review the publication )

Sci Signal, 2018, 11(530)

PubMed: 29764992 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2551-2563

PubMed: 30217967 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(7):1554-1565

PubMed: 29716963 ( click the link to review the publication )

Mol Cell Proteomics, 2018, 17(12):2434-2447

PubMed: 30217950 ( click the link to review the publication )

J Cell Mol Med, 2018, 22(11):5300-5310

PubMed: 30133120 ( click the link to review the publication )

Hum Gene Ther, 2018, 29(8):886-901

PubMed: 29641320 ( click the link to review the publication )

Sci Rep, 2018, 8(1):3521

PubMed: 29476067 ( click the link to review the publication )
Cell Signal, 2018, 52:137-146

PubMed: 30223016 ( click the link to review the publication )

Cancer Med, 2018, 7(11):5589-5603

PubMed: 30221846 ( click the link to review the publication )

Transl Oncol, 2018, 11(4):852-863

PubMed: 29753186 ( click the link to review the publication )

J Oncol, 2018, 2018:3979527

PubMed: 30631355 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(20):10724-10739

PubMed: 30202980 ( click the link to review the publication )

Cell Res, 2017, 27(2):274-293

PubMed: 27958289 ( click the link to review the publication )

Mol Cell, 2017, 67(4):579-593

PubMed: 28781233 ( click the link to review the publication )

Mol Cell, 2017, 68(1):210-223e6

PubMed: 28985505 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1506

PubMed: 29138396 ( click the link to review the publication )

Nat Commun, 2017, 8:15289

PubMed: 28474672 ( click the link to review the publication )

Aging Cell, 2017, 16(3):575-584

PubMed: 28345297 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 28994651 ( click the link to review the publication )

FASEB J, 2017, 32(2):625-638

PubMed: 28970258 ( click the link to review the publication )

Cell Chem Biol, 2017, 24(8):1017-1028

PubMed: 28807782 ( click the link to review the publication )

Cell Physiol Biochem, 2017, 43(2):431-444

PubMed: 28922657 ( click the link to review the publication )

Curr Biol, 2017, 27(10):1477-1484

PubMed: 28479321 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(1):3-15

PubMed: 27760837 ( click the link to review the publication )

FEBS J, 2017, 284(23):4035-4050

PubMed: 28985013 ( click the link to review the publication )

J Biol Chem, 2017, 292(36):15028-15038

PubMed: 28739871 ( click the link to review the publication )

Cell Signal, 2017, 39:74-83

PubMed: 28780319 ( click the link to review the publication )

Am J Physiol Cell Physiol, 2017, 313(5):C501-C515

PubMed: 28794108 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 484(4):864-870

PubMed: 28188792 ( click the link to review the publication )

Oncotarget, 2017, 9(13):10920-10933

PubMed: 29541386 ( click the link to review the publication )

Oncotarget, 2017, 8(23):37633-37645

PubMed: 28430578 ( click the link to review the publication )
Nat Chem Biol, 2016, 10.1038/nchembio.2017

PubMed: 26829474 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

Nat Commun, 2016, 7:10818

PubMed: 26912231 ( click the link to review the publication )

Nat Chem Biol, 2016, 12(6):411-8

PubMed: 27043190 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(1):48-59

PubMed: 26586723 ( click the link to review the publication )

J Virol, 2016, 90(6):2794-805

PubMed: 26719254 ( click the link to review the publication )

Sci Rep, 2016, 6:19567

PubMed: 26777522 ( click the link to review the publication )

J Biol Chem, 2016, 10.1074/jbc.M116.722751

PubMed: 27226586 ( click the link to review the publication )

J Biol Chem, 2016, 10.1074/jbc.M115.712745

PubMed: 27325694 ( click the link to review the publication )

J Biol Chem, 2016, 291(20):10904-15

PubMed: 27002159 ( click the link to review the publication )

Cell Cycle, 2016, 15(15):2009-18

PubMed: 27249336 ( click the link to review the publication )

PLoS One, 2016, 11(4):e0153818

PubMed: 27097159 ( click the link to review the publication )

Oncotarget, 2016, 7(18):26580-92

PubMed: 27058891 ( click the link to review the publication )

Head Neck, 2016, 10.1002/hed.24349

PubMed: 26713885 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(2):113-22

PubMed: ( click the link to review the publication )

Nat Cell Biol, 2015, 17(2):113-22

PubMed: 25599390 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(1):31-43

PubMed: 25503564 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(8):1024-35

PubMed: 26192437 ( click the link to review the publication )

Nat Commun, 2015, 6:8388

PubMed: 26399523 ( click the link to review the publication )

Nat Commun, 2015, 10.1038/ncomms8217

PubMed: 26147444 ( click the link to review the publication )

Nat Commun, 2015, 6:6891

PubMed: 25922916 ( click the link to review the publication )

Nat Commun, 2015, 6:8077

PubMed: 26293378 ( click the link to review the publication )

Nat Commun, 2015, 6:6946

PubMed: 25897860 ( click the link to review the publication )

Nat Commun, 2015, 6:10076

PubMed: 26647647 ( click the link to review the publication )
Nat Commun, 2015, 6:10072

PubMed: 26656453 ( click the link to review the publication )

Cancer Res, 2015, 75(2):405-14

PubMed: 25480943 ( click the link to review the publication )

J Control Release, 2015, 204:20-9

PubMed: 25681050 ( click the link to review the publication )

J Control Release, 2015, 204:20-29

PubMed: ( click the link to review the publication )

Cancer Lett, 2015, 357(2):591-601

PubMed: 25524551 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):527-43

PubMed: 25454348 ( click the link to review the publication )

Mol Cell Proteomics, 2015, 14(4):946-60

PubMed: 25659891 ( click the link to review the publication )

J Neurochem, 2015, 10.1111/jnc.13085

PubMed: 25727910 ( click the link to review the publication )

J Biol Chem, 2015, 290(5):3033-44

PubMed: 25505268 ( click the link to review the publication )

J Biol Chem, 2015, 290(49):29617-28

PubMed: 26468278 ( click the link to review the publication )

Mol Biol Cell, 2015, 26(3):440-52

PubMed: ( click the link to review the publication )

Cell Cycle, 2015, 14(2):219-31

PubMed: 25607646 ( click the link to review the publication )

Oncotarget, 2015, 6(4):2315-30

PubMed: 25537513 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5275-91

PubMed: 25779659 ( click the link to review the publication )

Oncotarget, 2015, 6(33):34475-93

PubMed: 26439686 ( click the link to review the publication )

Oncotarget, 2015, 6(4):2315-30

PubMed: 25537513 ( click the link to review the publication )

Nat Cell Biol, 2014, 16(6):538-49

PubMed: 24776885 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(12):3211-21

PubMed: 24771642 ( click the link to review the publication )

Cancer Res, 2014, 74(20):5878-90

PubMed: 25125659 ( click the link to review the publication )

ACS Chem Biol, 2014, 9(5):1160-71

PubMed: 24568369 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 13(5):1054-66

PubMed: 24748653 ( click the link to review the publication )

J Biol Chem, 2014, 289(38):26344-56

PubMed: 25100726 ( click the link to review the publication )

J Biol Chem, 2014, 289(18):12313-29

PubMed: 24634213 ( click the link to review the publication )

J Biol Chem, 2014, 289,14066-14074

PubMed: ( click the link to review the publication )
J Biol Chem, 2014, 289(20):14066-74

PubMed: 24706748 ( click the link to review the publication )

Cell Cycle, 2014, 13(2):303-14

PubMed: 24247149 ( click the link to review the publication )

Cell Cycle, 2014, 13(24):3867-77

PubMed: 25558830 ( click the link to review the publication )

Cell Cycle, 2014, 13(14):2248-61

PubMed: 24875404 ( click the link to review the publication )

Biosci Rep, 2014, 34(3)

PubMed: 24844881 ( click the link to review the publication )

PLoS One, 2014, 9(12):e115228

PubMed: 25542032 ( click the link to review the publication )

PLoS One, 2014, 8(10):e77053

PubMed: 24204733 ( click the link to review the publication )

Oncotarget, 2014, 5(3):667-78

PubMed: 24525428 ( click the link to review the publication )

The University of Queensland, 2014, Fawzi Faisal A. Bokhari

PubMed: ( click the link to review the publication )

Dev Cell, 2013, 25(6):555-71

PubMed: 23769972 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2013, 110(32):13026-31

PubMed: 23878225 ( click the link to review the publication )

Cancer Res, 2013, 73(22):6722-33

PubMed: 24101154 ( click the link to review the publication )

Cancer Res, 2013, 73(2):813-23

PubMed: 23144294 ( click the link to review the publication )

Cancer Res, 2013, 73(20):6310-22

PubMed: 24067506 ( click the link to review the publication )

Oncogene, 2013, 10.1038/onc.2013.518

PubMed: 24317508 ( click the link to review the publication )

Br J Cancer, 2013, 110(2):510-9

PubMed: 24327015 ( click the link to review the publication )

Gynecol Oncol, 2013, 128(3):461-9

PubMed: 23146687 ( click the link to review the publication )

J Biol Chem, 2013, 288(33):23765-75

PubMed: 23814058 ( click the link to review the publication )

J Biol Chem, 2013, 288(20):14158-69

PubMed: 23504319 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2013, 54(13):8353-63

PubMed: 24366665 ( click the link to review the publication )

Cancer Biol Ther, 2013, 14(5):436-49

PubMed: 23377828 ( click the link to review the publication )

PLoS One, 2013, 8(10):e77390

PubMed: 24155950 ( click the link to review the publication )

J Biomol Screen, 2013, 18(1):54-66

PubMed: 22923784 ( click the link to review the publication )

Biol Open, 2013, 2(5):479-86

PubMed: 23789096 ( click the link to review the publication )
J Biol Chem, 2012, 287(6):4376-85

PubMed: 22184120 ( click the link to review the publication )

J Biol Chem, 2012, 287(21):17088-99

PubMed: 22467873 ( click the link to review the publication )

Cell Cycle, 2012, 11(3):543-53

PubMed: 22262171 ( click the link to review the publication )

PLoS One, 2012, 7(6):e38838

PubMed: 22701722 ( click the link to review the publication )

Biotechniques, 2012, 10.2144/000113866

PubMed: ( click the link to review the publication )

Biotechniques, 2012, 53(1)

PubMed: 26307252 ( click the link to review the publication )

Nat Cell Biol, 2011, 13(10):1265-71

PubMed: 21874008 ( click the link to review the publication )

Cancer Res, 2011, 71(4):1385-95

PubMed: 21303981 ( click the link to review the publication )

Cancer Res, 2011, 71(17):5659-69

PubMed: 21693658 ( click the link to review the publication )

J Cell Biol, 2011, 193(6):1083-99

PubMed: 21646404 ( click the link to review the publication )

Oncogene, 2011, 30(46):4666-77

PubMed: 21602893 ( click the link to review the publication )

J Invest Dermatol, 2011, 131(9):1886-95

PubMed: 21654832 ( click the link to review the publication )

Purity & Quality Control

Choose Selective PLK Inhibitors

Biological Activity

Description

BI2536 is a potent Plk1 inhibitor with IC50 of 0.83 nM in a cell-free assay. It shows 4- and 11-fold greater selectivity against Plk2 and Plk3. Phase 2.

Features

The first potent and selective Plk1 inhibitor that induces all hallmarks of Plk1 inhibition.

Targets

PLK1 ^[1] (Cell-free assay)	PLK2 ^[1] (Cell-free assay)	PLK3 ^[1] (Cell-free assay)
0.83 nM	3.5 nM	9.0 nM

In vitro

BI 2536 blocks the activities of Plk2 and Plk3 to a slightly lesser extent with IC50 of 3.5 nM and 9.0 nM, respectively. In HeLa cells, BI 2536 treatment ranging from 10-100 nM leads to the blocking of the recruitment of γ-tubulin and phosphorylation of Apc6 at mitotic centrosomes, inhibition of cohesin release from chromosome arms, induction of monopolar spindles, as well as a range of other mitotic processes that are known to depend on Plk1. BI 2536 treatment leads to the HeLa cells arrested in G2/M, subsequently a sub-G1 DNA peak indicative of DNA breakdown and apoptosis, and accumulated cleaved PARP p85 fragments in a concentration-dependent manner. BI 2536 inhibits the growth of a panel of 32 human cancer cell lines with EC50 of 2-25 nM, while blocking the proliferation of exponentially growing hTERT-RPE1, human umbilical vein endothelial cells (HUVECs), and normal rat kidney (NRK) cells with EC50 of 12-31 nM. ^[1] Plk1 inhibition by BI 2536 reduces the growth and viability of anaplastic thyroid carcinoma (ATC) cells such as CAL62, OCUT-1, SW1736, 8505C, and ACT-1 with EC50 values of 1.4-5.6 nM. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
PSN1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1q3Z2lEPTB;MD6wNFc4PiEQvF2=	M1O2Z3NCVkeHUh?=
ACN	NH:0[49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV:4VppZUUN3ME2wMlAxQDR\|IN88US=>	NFTtZ5FUSU6JRWK=
TE-8	NVj5[oxVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M37yPWlEPTB;MD6wNFk1OSEQvF2=	NXjaNFRvW0GQR1XS
LC-2-ad	NWjYS\|dST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mk\hTWM2OD1yLkCxNFk{KM7:TR?=	M2foXnNCVkeHUh?=
ALL-PO	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUHJR\|UxRTBwMEGzJO69VQ>?	MVrTRW5ITVJ?
EW-16	NHS2SHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUOwTFF2UUN3ME2wMlAyOzN4IN88US=>	NIjrUnBUSU6JRWK=
KM12	M1LtWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXfRXXkyUUN3ME2wMlAyOzR6IN88US=>	M3XQdXNCVkeHUh?=
GI-1	Mny4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYP6RWtkUUN3ME2wMlAyOzh\|IN88US=>	M4roV3NCVkeHUh?=
LS-411N	M{faVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVvZe25UUUN3ME2wMlAyPDB5IN88US=>	MUnTRW5ITVJ?
ES8	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4DTU2lEPTB;MD6wNVQ6PCEQvF2=	M{LiVHNCVkeHUh?=
SNU-C2B	NY\EW\|FuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUDJR\|UxRTBwMEG1NlYh\|ryP	MoDnV2FPT0WU
CESS	NIq1bmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGWzRW9KSzVyPUCuNFE3ODJizszN	M4DwV3NCVkeHUh?=
697	NFzo[lBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEjrdllKSzVyPUCuNFE3PjhizszN	M3P5fXNCVkeHUh?=
NCI-H1963	M3jzSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3\iPWlEPTB;MD6wNVY4OyEQvF2=	MUTTRW5ITVJ?
IA-LM	M3fxXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{LpUmlEPTB;MD6wNVY5QCEQvF2=	NEjqSWNUSU6JRWK=
SW954	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX3JR\|UxRTBwMEG3NFUh\|ryP	NVX6ZZJWW0GQR1XS
RL95-2	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2n3XGlEPTB;MD6wNVc{QCEQvF2=	NXT1TXlwW0GQR1XS
LXF-289	M1;kS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NU\2XokzUUN3ME2wMlAyPzdizszN	MnHVV2FPT0WU
OCUB-M	NIXYRnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mo\RTWM2OD1yLkCxPFI3KM7:TR?=	NYHSSIVpW0GQR1XS
RKO	M4fEdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVj4ZpM1UUN3ME2wMlAyQTh5IN88US=>	NX3ldWRmW0GQR1XS
LOUCY	NH3DNlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1\nfmlEPTB;MD6wNlA2KM7:TR?=	NEnmcFJUSU6JRWK=
NOS-1	NI[2bYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH\NVm5KSzVyPUCuNFIxQTNizszN	MmS5V2FPT0WU
A4-Fuk	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXLsNHRNUUN3ME2wMlAzOjF6IN88US=>	Mom0V2FPT0WU
A388	NUDsNJV[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2faXWlEPTB;MD6wNlIzPyEQvF2=	MWnTRW5ITVJ?
TE-9	MnntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHy2b3VKSzVyPUCuNFIzPjFizszN	NXHMUnJNW0GQR1XS
KURAMOCHI	NUH2O5E6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoXDTWM2OD1yLkCyNlg2KM7:TR?=	NGm5SJdUSU6JRWK=
KALS-1	NGPLbI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnHWTWM2OD1yLkCyN\|M5KM7:TR?=	M1\veHNCVkeHUh?=
HOP-62	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXvJR\|UxRTBwMEK0NkDPxE1?	NFj2U5pUSU6JRWK=
RPMI-8402	NGfRNI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3PobmlEPTB;MD6wNlUxQCEQvF2=	MY\TRW5ITVJ?
TE-1	M4i5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFPCPYRKSzVyPUCuNFI2OTJizszN	M3O3VXNCVkeHUh?=
CCRF-CEM	MnfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlPWTWM2OD1yLkCyOVQ{KM7:TR?=	M{e2bnNCVkeHUh?=
HUTU-80	M3H5OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2\LNWlEPTB;MD6wNlYzPCEQvF2=	M33WcHNCVkeHUh?=
NCI-H1648	NH\UeI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3fnbGlEPTB;MD6wNlY1PyEQvF2=	MV;TRW5ITVJ?
HCE-4	MmT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF;GT25KSzVyPUCuNFI3QDJizszN	NH3QTFJUSU6JRWK=
ETK-1	M1:2UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MULJR\|UxRTBwMEK3N\|Yh\|ryP	NWX1S4JxW0GQR1XS
TE-15	NYXFZ5dUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF7wOXFKSzVyPUCuNFI4OzhizszN	M4rRcXNCVkeHUh?=
BE-13	MkfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXPJR\|UxRTBwMEK3OEDPxE1?	MUfTRW5ITVJ?
KE-37	MlX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NY\5TWFXUUN3ME2wMlAzPzRzIN88US=>	NF3ld4hUSU6JRWK=
NCI-H1355	NYLZb4YyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEjxR\|dKSzVyPUCuNFI4QDNizszN	MV\TRW5ITVJ?
TE-11	M4Kze2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV7rZnFRUUN3ME2wMlAzQDB7IN88US=>	M4nLOnNCVkeHUh?=
BL-70	NFXXOFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUPJR\|UxRTBwMEK4OVch\|ryP	M2W0O3NCVkeHUh?=
ES6	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWrNO4hvUUN3ME2wMlAzQDhzIN88US=>	MYTTRW5ITVJ?
GT3TKB	NHqwVYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUnJR\|UxRTBwMEK5OVMh\|ryP	M1TDW3NCVkeHUh?=
LB647-SCLC	NWG0SYpMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWjJR\|UxRTBwMEOxPVUh\|ryP	NHnDO25USU6JRWK=
NB13	M3fuO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGLwVIlKSzVyPUCuNFM{OTZizszN	MWnTRW5ITVJ?
ST486	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUP2cHBbUUN3ME2wMlA{OzN5IN88US=>	NWrsV21oW0GQR1XS
NCI-H82	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGfiZpdKSzVyPUCuNFM{PDNizszN	NX\Hcm9RW0GQR1XS
NTERA-S-cl-D1	M3PBUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWfJR\|UxRTBwMEOzPVkh\|ryP	MUDTRW5ITVJ?
ES4	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUXJR\|UxRTBwMEO0OlMh\|ryP	NEPneHBUSU6JRWK=
SK-NEP-1	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4DrZ2lEPTB;MD6wN\|Q6QSEQvF2=	NELB[plUSU6JRWK=
Becker	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFTKcnRKSzVyPUCuNFM2PTVizszN	NFexdmZUSU6JRWK=
A101D	NWLX[lFRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3rMSmlEPTB;MD6wN\|c1QCEQvF2=	NUXqVIpIW0GQR1XS
SK-UT-1	NX;iN41{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEDPcVJKSzVyPUCuNFM4PzRizszN	NWTOemUxW0GQR1XS
SW982	MoLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mnv5TWM2OD1yLkCzO\|kh\|ryP	NInFR4JUSU6JRWK=
TE-10	Mlr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWntOpZQUUN3ME2wMlA1ODR4IN88US=>	NVzBOYI2W0GQR1XS
OVCAR-4	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXjJR\|UxRTBwMESwOVkh\|ryP	NV7FcmlJW0GQR1XS
KP-N-YS	M4\CWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXjBcY1TUUN3ME2wMlA1ODh3IN88US=>	MYfTRW5ITVJ?
BL-41	NVP0dGU5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlHDTWM2OD1yLkC0NVI2KM7:TR?=	MXvTRW5ITVJ?
MZ1-PC	NUe4UGxLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYHJR\|UxRTBwMESxNlch\|ryP	NFPkUZZUSU6JRWK=
PF-382	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGfXW2RKSzVyPUCuNFQyQThizszN	Mn;rV2FPT0WU
MOLT-13	MmPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVHJR\|UxRTBwMESyN\|gh\|ryP	MXvTRW5ITVJ?
HCC1599	NXTrNYFIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1;hbGlEPTB;MD6wOFI2QCEQvF2=	MojUV2FPT0WU
IST-MEL1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1XS[mlEPTB;MD6wOFQ1OiEQvF2=	NUPYdmhsW0GQR1XS
LU-139	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYPydVFsUUN3ME2wMlA1PDR{IN88US=>	NX;Lcmh2W0GQR1XS
MS-1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4OzcGlEPTB;MD6wOFcxOSEQvF2=	MlTMV2FPT0WU
MFH-ino	NFLjUZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYf4eFlTUUN3ME2wMlA2ODB\|IN88US=>	NU\RUmZZW0GQR1XS
IMR-5	MnLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnvETWM2OD1yLkC1NFIyKM7:TR?=	NW\hdlJRW0GQR1XS
TE-5	NYDte3VYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml7UTWM2OD1yLkC1NFY{KM7:TR?=	NVHnTWVnW0GQR1XS
DJM-1	NX\JT3V7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnTMTWM2OD1yLkC1NVQzKM7:TR?=	NYLpSZp4W0GQR1XS
NB17	NWHTdpJCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXHJR\|UxRTBwMEWyNFch\|ryP	MXfTRW5ITVJ?
KARPAS-45	NUTWdGlNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mnu3TWM2OD1yLkC1N\|U5KM7:TR?=	NWXLboRNW0GQR1XS
TGBC1TKB	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3[wdWlEPTB;MD6wOVQxPSEQvF2=	NHfNZoVUSU6JRWK=
ML-2	MmnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVXJR\|UxRTBwMEW0NVQh\|ryP	Ml;CV2FPT0WU
no-10	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWnJR\|UxRTBwMEW0O\|Qh\|ryP	NXjneVZVW0GQR1XS
CTV-1	NYXrdpRtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{Pk[2lEPTB;MD6wOVUxOiEQvF2=	MXHTRW5ITVJ?
SJSA-1	NYTOTZRQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4SzdGlEPTB;MD6wOVUzKM7:TR?=	NWXYcJNwW0GQR1XS
HC-1	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHvBWVJKSzVyPUCuNFU2QTdizszN	NXvCenVwW0GQR1XS
TE-12	NVvGPGs6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4X4eWlEPTB;MD6wOVYyOyEQvF2=	NWL6NGhHW0GQR1XS
KY821	NYnPcHdRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1;w[GlEPTB;MD6wOVY{OiEQvF2=	M3LSdHNCVkeHUh?=
TALL-1	M4DreGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnHVTWM2OD1yLkC1O\|A5KM7:TR?=	NWC0Ro93W0GQR1XS
DEL	M4Dqc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4PuUGlEPTB;MD6wOVcxQSEQvF2=	NGnCcnlUSU6JRWK=
TE-6	NGLIfG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXTn[W1KUUN3ME2wMlA2PzJ{IN88US=>	M1vCW3NCVkeHUh?=
SK-LMS-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{nWNGlEPTB;MD6wOVgxPSEQvF2=	NVLvXWRoW0GQR1XS
EW-1	NVLmb5RiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF\hS\|VKSzVyPUCuNFU5OzdizszN	M1fPUXNCVkeHUh?=
8-MG-BA	M1n0UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFvrU5RKSzVyPUCuNFU5PTFizszN	MXjTRW5ITVJ?
NALM-6	NFflbGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX:wU4p6UUN3ME2wMlA2QTd\|IN88US=>	MkHHV2FPT0WU
LB771-HNC	M1HvcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHWxdmZKSzVyPUCuNFU6PzlizszN	NEPUOVBUSU6JRWK=
HT-144	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVnJR\|UxRTBwME[xN{DPxE1?	MmDRV2FPT0WU
KM-H2	M4LHXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlmzTWM2OD1yLkC2NlIyKM7:TR?=	NFT4fpFUSU6JRWK=
SF268	NGnQTlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV;JR\|UxRTBwME[yPFYh\|ryP	NGnPT4xUSU6JRWK=
RS4-11	NVnmXpk{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoexTWM2OD1yLkC2N\|A1KM7:TR?=	NEPFdIxUSU6JRWK=
MHH-PREB-1	Mn;PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV65Z5RHUUN3ME2wMlA3OzF7IN88US=>	NFi5dIxUSU6JRWK=
ATN-1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2jpcGlEPTB;MD6wOlM1PSEQvF2=	MlLoV2FPT0WU
BB30-HNC	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{Wyc2lEPTB;MD6wOlQ{PiEQvF2=	NHLMV4dUSU6JRWK=
CPC-N	M2\qWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWDJR\|UxRTBwME[1NlQh\|ryP	MkjrV2FPT0WU
NB1	NX[4bGVuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV\JR\|UxRTBwME[2NVMh\|ryP	NYTEOGhbW0GQR1XS
KS-1	NFPMfWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWnJR\|UxRTBwME[3OFgh\|ryP	NYfFdoNtW0GQR1XS
RXF393	NXX4TmZpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFXsZmtKSzVyPUCuNFY4PjRizszN	NXjRTHdwW0GQR1XS
IST-SL2	NHLLfGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX3JR\|UxRTBwMEewNFQh\|ryP	Ml\nV2FPT0WU
GI-ME-N	NInBRndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFnvcJRKSzVyPUCuNFczQDZizszN	NEf1cnpUSU6JRWK=
VA-ES-BJ	NEHSWm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MU\JR\|UxRTBwMEe0O\|Uh\|ryP	MUjTRW5ITVJ?
NCI-H1581	M1fHXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoH2TWM2OD1yLkC3OFc5KM7:TR?=	MWfTRW5ITVJ?
U-266	MnzoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIHi[plKSzVyPUCuNFc1QTdizszN	NYD2Zoh{W0GQR1XS
DMS-114	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkHPTWM2OD1yLkC3OVI5KM7:TR?=	NFjkb\|VUSU6JRWK=
NCI-H187	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml;hTWM2OD1yLkC3O\|I3KM7:TR?=	NVXONWQ{W0GQR1XS
SW962	NXXOfpJET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4PwUmlEPTB;MD6wO\|g{QSEQvF2=	MnPCV2FPT0WU
MONO-MAC-6	M2rxVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVnJR\|UxRTBwMEe5PFYh\|ryP	MWfTRW5ITVJ?
MOLT-16	NYToSohjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV;JR\|UxRTBwMEixNlEh\|ryP	NYrtU4E6W0GQR1XS
KNS-42	NULPWGZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUDJR\|UxRTBwMEixOlEh\|ryP	Mne2V2FPT0WU
CMK	NGexcFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHvJT4JKSzVyPUCuNFgzOjVizszN	NF3CUIJUSU6JRWK=
Ramos-2G6-4C10	NFHmdFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NE\ndpdKSzVyPUCuNFgzOjVizszN	MUnTRW5ITVJ?
Daudi	M3m3[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnjNTWM2OD1yLkC4NlU3KM7:TR?=	M17IfHNCVkeHUh?=
NCI-H510A	M4H3bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NULyZ49VUUN3ME2wMlA5OzN4IN88US=>	NEXudnhUSU6JRWK=
LB831-BLC	NXHwcmJsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFT0b2RKSzVyPUCuNFg2PjFizszN	Mo\VV2FPT0WU
HEL	NHPiOYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkXmTWM2OD1yLkC4OlY5KM7:TR?=	MnHNV2FPT0WU
LU-134-A	NXnaepdiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX3aeWUxUUN3ME2wMlA5PzB6IN88US=>	NXTiNHBZW0GQR1XS
NCI-H1694	NHO0bodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoLrTWM2OD1yLkC4O\|Q1KM7:TR?=	M1TIU3NCVkeHUh?=
KGN	NY\RdG1NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXnJR\|UxRTBwMEi3OVkh\|ryP	MVfTRW5ITVJ?
A253	Ml;US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYexcmJQUUN3ME2wMlA5QDJ{IN88US=>	NGe1eGtUSU6JRWK=
DG-75	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3yzT2lEPTB;MD6wPFkzOiEQvF2=	NW\VPZZMW0GQR1XS
MOLT-4	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHPPfIdKSzVyPUCuNFg6QDNizszN	MXrTRW5ITVJ?
NCI-SNU-5	NYnSTphDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYPJR\|UxRTBwMEmyOVgh\|ryP	NWnxSnF5W0GQR1XS
ONS-76	NETENIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH3ueoFKSzVyPUCuNFkzPzZizszN	MX;TRW5ITVJ?
NCI-H446	NFzhNYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIH2Xo1KSzVyPUCuNFk1PjJizszN	NUfLZ2E5W0GQR1XS
COR-L279	NH7DVGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmDRTWM2OD1yLkC5OVU3KM7:TR?=	M3LkfXNCVkeHUh?=
Calu-6	MnzyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXjJR\|UxRTBwMEm1PVgh\|ryP	NVnOe2R7W0GQR1XS
BC-3	Mn;vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3rqT2lEPTB;MD6wPVY3OiEQvF2=	NFPFbnBUSU6JRWK=
NCI-H2126	M{LQZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYjtTnNHUUN3ME2wMlA6PzlzIN88US=>	NFPUNIlUSU6JRWK=
NCI-H1882	NEnkSZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2XyfmlEPTB;MD6wPVgxQSEQvF2=	NH\nVo9USU6JRWK=
BB65-RCC	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWjjR4lQUUN3ME2wMlExOjl2IN88US=>	NUDrUmxMW0GQR1XS
DU-4475	NHzybXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGXQdXhKSzVyPUCuNVA1ODdizszN	NV\BRml6W0GQR1XS
NCI-H526	NUO1NpN5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEG5e5RKSzVyPUCuNVA1PCEQvF2=	NXz3epREW0GQR1XS
NEC8	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXfsOI5iUUN3ME2wMlExPTJ3IN88US=>	NEfjWJZUSU6JRWK=
NCI-H1304	NEG1SYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3nyUGlEPTB;MD6xNFU6PCEQvF2=	MkXsV2FPT0WU
L-540	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXvrPWNWUUN3ME2wMlExPzB6IN88US=>	NVzRVpJbW0GQR1XS
NCI-SNU-16	NIfUWI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NI\nRXZKSzVyPUCuNVA4PDJizszN	MVfTRW5ITVJ?
HD-MY-Z	M1m5XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml7jTWM2OD1yLkGwPFU3KM7:TR?=	NXnDPHpvW0GQR1XS
K-562	M3q2R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF3tfXJKSzVyPUCuNVA5PThizszN	MUTTRW5ITVJ?
JAR	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGHlNnFKSzVyPUCuNVA6OjVizszN	MonNV2FPT0WU
MZ2-MEL	MkLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUDYUYRlUUN3ME2wMlEyODVizszN	NYDHfplbW0GQR1XS
L-363	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoXDTWM2OD1yLkGxNFc6KM7:TR?=	MX\TRW5ITVJ?
BV-173	NY\lO4ZyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXPzVpdTUUN3ME2wMlEyOjR\|IN88US=>	MlvnV2FPT0WU
NCI-H524	NFzDb2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{jQRmlEPTB;MD6xNVI4PCEQvF2=	MoXIV2FPT0WU
EoL-1-cell	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYDJR\|UxRTBwMUG2O\|Ih\|ryP	Mom1V2FPT0WU
K052	NELWfIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRTBwMUG3NVIh\|ryP	NIjCWYxUSU6JRWK=
TK10	M4LkfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1ixdmlEPTB;MD6xNVczQCEQvF2=	NFzz[5FUSU6JRWK=
KU812	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFjLdINKSzVyPUCuNVIxPDRizszN	MkK5V2FPT0WU
RPMI-8226	MorLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXTJR\|UxRTBwMUKwOVIh\|ryP	M2rQd3NCVkeHUh?=
MZ7-mel	NF\DOppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NETHRWJKSzVyPUCuNVIzOzdizszN	MUjTRW5ITVJ?
SK-PN-DW	NV7lXlB6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2j4XWlEPTB;MD6xNlI5PyEQvF2=	NGO3NnVUSU6JRWK=
SR	M2DrR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2joR2lEPTB;MD6xNlQ1OSEQvF2=	M4HL[HNCVkeHUh?=
RPMI-6666	M3HHc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYnoZ\|FQUUN3ME2wMlEzPzR\|IN88US=>	MlXkV2FPT0WU
no-11	MnrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXXJR\|UxRTBwMUK4Olkh\|ryP	NX\5cnVuW0GQR1XS
EW-3	NX7CSIlnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWD2THVQUUN3ME2wMlEzQDl\|IN88US=>	NWnS[4s{W0GQR1XS
LAMA-84	MoXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3T6e2lEPTB;MD6xN\|E5PyEQvF2=	Ml;FV2FPT0WU
HT	MmKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmnGTWM2OD1yLkGzOVc1KM7:TR?=	MWrTRW5ITVJ?
KP-N-RT-BM-1	NY\qeFlpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXroOYQ2UUN3ME2wMlE{PjF{IN88US=>	NGW3bpNUSU6JRWK=
NCI-H747	MnLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYLzXpVxUUN3ME2wMlE{PyEQvF2=	NXi2[2lLW0GQR1XS
NCCIT	M3jsV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVPJR\|UxRTBwMUO5N\|kh\|ryP	NF3scXdUSU6JRWK=
MLMA	NV7MN\|NNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGXobY5KSzVyPUCuNVQyPjdizszN	NYT6OmIzW0GQR1XS
LP-1	NVfnT\|NZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1\lUWlEPTB;MD6xOFI1KM7:TR?=	NYKw[VgyW0GQR1XS
CAL-148	Mni1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkDxTWM2OD1yLkG0OFg{KM7:TR?=	M172W3NCVkeHUh?=
GB-1	M1TXd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{PaW2lEPTB;MD6xOFUzPiEQvF2=	M1;NW3NCVkeHUh?=
COR-L88	NX\YZ2xUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkTvTWM2OD1yLkG0PFAzKM7:TR?=	NXXKUGtxW0GQR1XS
NKM-1	M2TkUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYPL[GEzUUN3ME2wMlE1QTB4IN88US=>	NFPOZ2FUSU6JRWK=
NB5	NUDWTIl3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVrJR\|UxRTBwMUW0OlIh\|ryP	NXz5dHJZW0GQR1XS
SH-4	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUi2WGRHUUN3ME2wMlE2PDZ4IN88US=>	NI\GSHVUSU6JRWK=
EM-2	M3LLWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MojaTWM2OD1yLkG1OFY4KM7:TR?=	NVSxV3NTW0GQR1XS
TGBC24TKB	NHj3TXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIXzZolKSzVyPUCuNVU3PTlizszN	MUTTRW5ITVJ?
SCLC-21H	MmPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NW\ZemFHUUN3ME2wMlE2PzB{IN88US=>	NWHv[41PW0GQR1XS
COLO-684	M1zQPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXPJR\|UxRTBwMUW3NlEh\|ryP	NEP0PHZUSU6JRWK=
KINGS-1	NGGzUXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXzHOpZ4UUN3ME2wMlE2QTFizszN	M4P5WnNCVkeHUh?=
LS-123	NVy3NJg3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mm\LTWM2OD1yLkG1PVE4KM7:TR?=	MojmV2FPT0WU
MC116	NF[0emVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIfUZYFKSzVyPUCuNVYyPThizszN	NYDJNlNUW0GQR1XS
SU-DHL-1	NXXXd3I2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnnrTWM2OD1yLkG2NlA3KM7:TR?=	NETGTJdUSU6JRWK=
NCI-H64	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV;RbplTUUN3ME2wMlE3OzR5IN88US=>	NXLpS4QzW0GQR1XS
HCE-T	M3LhZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHHyNlRKSzVyPUCuNVY2ODRizszN	MnvEV2FPT0WU
LOXIMVI	NXvhVWlQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXnwR4hYUUN3ME2wMlE3QTR7IN88US=>	MUnTRW5ITVJ?
ARH-77	NXHybWNoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGfZU2lKSzVyPUCuNVc{PzlizszN	MV;TRW5ITVJ?
DOHH-2	MlPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3HSWmlEPTB;MD6xO\|Y4OiEQvF2=	M{i5b3NCVkeHUh?=
COLO-320-HSR	M3X4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlTGTWM2OD1yLkG4NVU1KM7:TR?=	NVzqUHJoW0GQR1XS
NB6	M1jpVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWi3VGNEUUN3ME2wMlE5PTZ4IN88US=>	NEXYNpVUSU6JRWK=
L-428	NEHrNmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVS1WnZuUUN3ME2wMlE5QDF\|IN88US=>	NUjWOVBNW0GQR1XS
SNB75	MnvES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH;meZRKSzVyPUCuNVg5OjRizszN	NI\jWZBUSU6JRWK=
NCI-H2141	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2nlcWlEPTB;MD6xPVAyOSEQvF2=	NGXnTZdUSU6JRWK=
KARPAS-299	NVHk[m57T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYTPW2ZjUUN3ME2wMlE6OjRzIN88US=>	NVWySnlEW0GQR1XS
LC4-1	MofTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{DLbWlEPTB;MD6xPVUxOiEQvF2=	Mnf4V2FPT0WU
UACC-257	NITqNVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mmq1TWM2OD1yLkG5PVQ4KM7:TR?=	NELpOnhUSU6JRWK=
EVSA-T	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmnYTWM2OD1yLkKwN\|EzKM7:TR?=	NUG5Vo1ZW0GQR1XS
JiyoyeP-2003	NWexeFJFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1TzUWlEPTB;MD6yNFQ4PyEQvF2=	M3PBb3NCVkeHUh?=
NCI-H720	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHnaN2NKSzVyPUCuNlA2OjVizszN	NHvVSo5USU6JRWK=
GAK	M2OzXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGHXU\|lKSzVyPUCuNlEyQDlizszN	NX3LPZVmW0GQR1XS
HH	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlvnTWM2OD1yLkKxOFA2KM7:TR?=	NGXZeYVUSU6JRWK=
NCI-H1436	Mk\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MojkTWM2OD1yLkKxOFY1KM7:TR?=	NULaV4JiW0GQR1XS
GR-ST	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmnxTWM2OD1yLkKxOFg5KM7:TR?=	M{jYTHNCVkeHUh?=
BC-1	NIjGXolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnGwTWM2OD1yLkKyOlE3KM7:TR?=	NWfadGs3W0GQR1XS
SIG-M5	MlP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MW\JR\|UxRTBwMkK3Nlch\|ryP	MljrV2FPT0WU
NCI-H345	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlHxTWM2OD1yLkKzPFA2KM7:TR?=	NYTwfohiW0GQR1XS
OPM-2	NEnDWWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF7IR4pKSzVyPUCuNlM5QDJizszN	NVrWcYR1W0GQR1XS
LB1047-RCC	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV7JR\|UxRTBwMkS0NUDPxE1?	M1X6XnNCVkeHUh?=
CTB-1	NXThc3NPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlPqTWM2OD1yLkK0OFk{KM7:TR?=	MW\TRW5ITVJ?
A3-KAW	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mny3TWM2OD1yLkK1N\|QyKM7:TR?=	NXrrW3pFW0GQR1XS
SF126	NFLaWlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NI[5RYNKSzVyPUCuNlU{QDNizszN	Mlz5V2FPT0WU
KARPAS-422	Mmq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVzlPINyUUN3ME2wMlI2PDN3IN88US=>	MYfTRW5ITVJ?
MEG-01	M1niTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEjFVpNKSzVyPUCuNlU3PzNizszN	MoC3V2FPT0WU
NCI-H209	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHLxW4lKSzVyPUCuNlY{PzRizszN	M3TDbXNCVkeHUh?=
SBC-1	M3TOOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIO2c4RKSzVyPUCuNlY2KM7:TR?=	NX:yXodmW0GQR1XS
K5	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlnXTWM2OD1yLkK2PVg1KM7:TR?=	NX;5Z4pMW0GQR1XS
QIMR-WIL	NXrtZYJDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoTaTWM2OD1yLkK3NVU2KM7:TR?=	NHHM[nVUSU6JRWK=
NMC-G1	NEW4[m5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkDzTWM2OD1yLkK4NlE4KM7:TR?=	NGDmS3RUSU6JRWK=
IST-MES1	MnfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIO1VFJKSzVyPUCuNlkzOzhizszN	MlX4V2FPT0WU
SW684	MnfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{TmZWlEPTB;MD6zNFA1PyEQvF2=	MnnyV2FPT0WU
MV-4-11	M4n3[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIXiUWhKSzVyPUCuN\|A4QDhizszN	MVHTRW5ITVJ?
LAN-6	NHfLUmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVPJR\|UxRTBwM{G1O\|Ih\|ryP	M3jPOHNCVkeHUh?=
RH-1	NGfSd\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEiwS\|lKSzVyPUCuN\|E5PzFizszN	MnHJV2FPT0WU
CP66-MEL	M4W0fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXXJR\|UxRTBwM{G4O\|gh\|ryP	MnHQV2FPT0WU
EC-GI-10	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NED3XpVKSzVyPUCuN\|I6QDdizszN	MXPTRW5ITVJ?
GDM-1	M1PxVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmLnTWM2OD1yLkOzNFU6KM7:TR?=	MWHTRW5ITVJ?
IST-SL1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MknkTWM2OD1yLkO0PVE1KM7:TR?=	NFT3ZWhUSU6JRWK=
KMOE-2	MlzNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUXBRnBuUUN3ME2wMlM2OTd3IN88US=>	NGTFbnNUSU6JRWK=
OS-RC-2	NF;jTFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFjiOYNKSzVyPUCuN\|U2PDRizszN	M1jTUnNCVkeHUh?=
HDLM-2	MnH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWLZT4o5UUN3ME2wMlM4QDF2IN88US=>	NVjYcphKW0GQR1XS
DSH1	M3fqWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1jFSWlEPTB;MD6zPFY{OSEQvF2=	MULTRW5ITVJ?
LS-1034	Mmq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1roNGlEPTB;MD6zPFk2PCEQvF2=	NWHEU40yW0GQR1XS
LB373-MEL-D	NIWwbWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NU\Ue\|RpUUN3ME2wMlM6OTl5IN88US=>	NFK3d3FUSU6JRWK=
GOTO	MlrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVrJR\|UxRTBwNEKxNVgh\|ryP	NYTxSnhtW0GQR1XS
MRK-nu-1	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIfObXhKSzVyPUCuOFIzODVizszN	NGHTOWdUSU6JRWK=
SK-MM-2	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXzJR\|UxRTBwNEO0OFIh\|ryP	M4DTPHNCVkeHUh?=
BOKU	Ml7RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1r2cWlEPTB;MD60N\|c6OiEQvF2=	NVvBWmxmW0GQR1XS
NOMO-1	Ml24S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUDJR\|UxRTBwNEO4OkDPxE1?	NVjmOVRGW0GQR1XS
J-RT3-T3-5	NXj3[\|lIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{\y[GlEPTB;MD60OFg4QCEQvF2=	M4PQRnNCVkeHUh?=
COLO-668	MoTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoHiTWM2OD1yLkS1OlY5KM7:TR?=	M1rPS3NCVkeHUh?=
SF539	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX3TNmRtUUN3ME2wMlQ5Pjh2IN88US=>	MojtV2FPT0WU
LB2518-MEL	NIjRdVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYnJR\|UxRTBwNEm3NFMh\|ryP	MkD3V2FPT0WU
TE-441-T	M{DUWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2jscmlEPTB;MD61NFEzKM7:TR?=	NVTzTWxnW0GQR1XS
MDA-MB-134-VI	M2DOZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3;UWGlEPTB;MD61NFkzOSEQvF2=	NHXqN\|RUSU6JRWK=
SCC-3	NHLPVIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEHEWY9KSzVyPUCuOVE5PzNizszN	MorZV2FPT0WU
KLE	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVTPOG14UUN3ME2wMlUzOTdzIN88US=>	NYTCeoZJW0GQR1XS
LB2241-RCC	NGfmdZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1PjfWlEPTB;MD61NlUzPSEQvF2=	MXLTRW5ITVJ?
NCI-H1417	Mlq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEjUUphKSzVyPUCuOVM1OzVizszN	NV:1V2V4W0GQR1XS
NCI-H2081	NWjHfoJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGT3e4hKSzVyPUCuOVg3OTFizszN	NEfMcGRUSU6JRWK=
NCI-H1522	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVj2eVdKUUN3ME2wMlU6Ozh\|IN88US=>	M4LzRXNCVkeHUh?=
NCI-H889	NYroOppLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlrXTWM2OD1yLkW5PFQ1KM7:TR?=	M3HZNnNCVkeHUh?=
CGTH-W-1	MknkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M165bWlEPTB;MD62NFc2PSEQvF2=	NFr0fHpUSU6JRWK=
EB-3	MkXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV\mOGZvUUN3ME2wMlYyOTV\|IN88US=>	M3L1enNCVkeHUh?=
D-336MG	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MU\JR\|UxRTBwNkG3PVEh\|ryP	M{PsUnNCVkeHUh?=
LC-1F	NUDydHBvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX:yNWxyUUN3ME2wMlYzPTl{IN88US=>	NHHEeG1USU6JRWK=
MHH-NB-11	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH;ic2pKSzVyPUCuOlM5ODFizszN	MV3TRW5ITVJ?
SK-N-FI	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1OyTmlEPTB;MD62N\|kyKM7:TR?=	M4rKbnNCVkeHUh?=
NCI-H69	NUfWcG84T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYHy[4VoUUN3ME2wMlY1QDd7IN88US=>	NHXVRY5USU6JRWK=
SCH	NV7UT\|VOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUXQTJZWUUN3ME2wMlY3ODJ\|IN88US=>	MVLTRW5ITVJ?
LS-513	NFnHeW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlL3TWM2OD1yLk[3NlU6KM7:TR?=	NF\zbXhUSU6JRWK=
CP67-MEL	NGjk[o5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn3HTWM2OD1yLk[3OVk3KM7:TR?=	MlHpV2FPT0WU
GCIY	NXu0SnZJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MY\JR\|UxRTBwN{CzOlMh\|ryP	NHjC[FlUSU6JRWK=
SHP-77	NU\qeYVWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2WxfGlEPTB;MD63NFc{PCEQvF2=	NYXjVZZ7W0GQR1XS
EHEB	Mly4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Moq1TWM2OD1yLkexPFU1KM7:TR?=	MUTTRW5ITVJ?
D-247MG	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmPnTWM2OD1yLkezNlMzKM7:TR?=	MV3TRW5ITVJ?
Raji	NHm5UnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M33RdWlEPTB;MD63OFk5QSEQvF2=	M4fXe3NCVkeHUh?=
MPP-89	MnTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEPEfmlKSzVyPUCuO\|U6PzhizszN	M{TTTnNCVkeHUh?=
EKVX	M1nMSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NULUdHRqUUN3ME2wMlc6ODd\|IN88US=>	M1TpR3NCVkeHUh?=
HCC2218	NEPsbIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{DSemlEPTB;MD63PVE{OSEQvF2=	MVXTRW5ITVJ?
KNS-81-FD	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVTJR\|UxRTBwOEGwNVEh\|ryP	NGT2ZWJUSU6JRWK=
HCC2157	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV3JR\|UxRTBwOES5OVEh\|ryP	Mk\EV2FPT0WU
BT-474	NE\FW2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEfGfoNKSzVyPUCuPFg5PTRizszN	NHfoZ4hUSU6JRWK=
NCI-H748	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3K5NWlEPTB;MD65NVIh\|ryP	NYPTbnp3W0GQR1XS
EW-24	NEO5NFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUfJR\|UxRTBwOUKwNFIh\|ryP	MV;TRW5ITVJ?
D-263MG	NHOzWJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3PYSWlEPTB;MD65OFUyOiEQvF2=	NGqwb2lUSU6JRWK=
OMC-1	NIP5clVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXnJR\|UxRTBwOU[zO\|Mh\|ryP	NVvrdFc6W0GQR1XS
NCI-H2196	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmrxTWM2OD1yLkm3O\|c4KM7:TR?=	NUnkZ496W0GQR1XS
HAL-01	M3TtWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUfZbI1XUUN3ME2wMlk6QDd{IN88US=>	MYDTRW5ITVJ?
NCI-H2107	NUDiemZyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnjRTWM2OD1zLkCxPFU1KM7:TR?=	MWDTRW5ITVJ?
LB996-RCC	NH\nfXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1vNTmlEPTB;MT6wPFA2OSEQvF2=	MVPTRW5ITVJ?
NCI-H1395	MlvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXf0RmpFUUN3ME2xMlExPjdizszN	NGKydpJUSU6JRWK=
CHP-126	MnLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYXJR\|UxRTFwMU[xPVkh\|ryP	M37mV3NCVkeHUh?=
NB69	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVrJR\|UxRTFwMk[xOFgh\|ryP	NGjydY9USU6JRWK=
CAS-1	NWLPdWpqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4HpXmlEPTB;MT6zOFI{OSEQvF2=	NYLxfW1kW0GQR1XS
JVM-3	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3rzb2lEPTB;MT60O\|g2PSEQvF2=	M3HBOXNCVkeHUh?=
DMS-153	NXm4UoFYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2XKdGlEPTB;MT61O\|Y4PCEQvF2=	M4[5fHNCVkeHUh?=
SK-MEL-2	NVS4VoF2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{Xj[mlEPTB;MT63NVc5QSEQvF2=	MnvhV2FPT0WU
NCI-H1155	M3Kzc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXLJR\|UxRTFwN{O2O\|Yh\|ryP	M3HxT3NCVkeHUh?=
NCI-H1092	MnzrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2HzSmlEPTB;MT63OlE5OiEQvF2=	M3\KOHNCVkeHUh?=
LU-165	NHraS3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoDsTWM2OD1zLki2OFc3KM7:TR?=	NH2yT5RUSU6JRWK=
HL-60	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWf2XW83UUN3ME2xMlk6QTB6IN88US=>	NYPMdXlHW0GQR1XS
REH	NFPoUYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3i1UWlEPTB;Mj6wNFU5OiEQvF2=	MXzTRW5ITVJ?
JVM-2	NX\UPGlzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NE\QS2RKSzVyPUKuNFYyOzVizszN	NXfnVHFEW0GQR1XS
MN-60	NHi0fZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGjXcXpKSzVyPUKuNVc{ODhizszN	NYXjeFV5W0GQR1XS
SCC-15	NUjQW4JwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYHJR\|UxRTJwMkCyO{DPxE1?	NXGxcldOW0GQR1XS
SNU-C1	NXG5eJRKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2PpeGlEPTB;Mj6yNVM1OyEQvF2=	NFHuOGFUSU6JRWK=
SK-MEL-1	NXTLeG5bT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX3Gc2pEUUN3ME2yMlMzODR5IN88US=>	NEfN[plUSU6JRWK=
TGW	M17ufWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXLJR\|UxRTJwM{WwNlch\|ryP	M4XsZ3NCVkeHUh?=
CA46	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUjjeJdIUUN3ME2yMlc2QTZ5IN88US=>	Mk[4V2FPT0WU
NCI-H23	Ml2zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGfN[XVKSzVyPUKuPFA4QTFizszN	NGHZdoFUSU6JRWK=
MMAC-SF	M3PWb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGXNU4dKSzVyPUKuPFY3OjhizszN	M2DSXXNCVkeHUh?=
NCI-H2171	NGG2e3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH;QbnVKSzVyPUOuNFM1PDhizszN	M2jsTHNCVkeHUh?=
A704	M1e5eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUDJR\|UxRTNwMUSxPVQh\|ryP	NHqybodUSU6JRWK=
DB	M1SwT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1\RXmlEPTB;Mz6yOVU4PiEQvF2=	Moq5V2FPT0WU
NCI-H719	Ml[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{PORmlEPTB;Mz6zNFM5PCEQvF2=	M3vhS3NCVkeHUh?=
MC-CAR	MmTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIPONYNKSzVyPUOuOVQ5OTdizszN	M4jrenNCVkeHUh?=
SIMA	NITFcnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2[4eGlEPTB;Mz61PFQyPiEQvF2=	MnLwV2FPT0WU
SW872	NGLwNVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2LUS2lEPTB;Mz63PFExOSEQvF2=	MX;TRW5ITVJ?
HCC1187	MkjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUnJR\|UxRTNwN{izNVUh\|ryP	NWDwe2M{W0GQR1XS
EW-13	M4rQb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXHuUoFFUUN3ME2zMlg{PDF5IN88US=>	MoK2V2FPT0WU
NCI-SNU-1	NUS4eoxWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3\aSmlEPTB;ND6yNVk6QSEQvF2=	NGXOWZhUSU6JRWK=
NCI-H226	M1e2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUnJR\|UxRTRwM{O2NFYh\|ryP	M{X6TXNCVkeHUh?=
RPMI-8866	NULic21UT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVfJR\|UxRTRwM{[wNlkh\|ryP	M1;rNnNCVkeHUh?=
OCI-AML2	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVrJR\|UxRTRwNUWyN{DPxE1?	M2jUSXNCVkeHUh?=
LU-65	NX25R2pvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH35dolKSzVyPUSuPVMxOzNizszN	NXzETVVIW0GQR1XS
SK-N-DZ	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXTJR\|UxRTVwNkO0OlUh\|ryP	NUH4b4pDW0GQR1XS
NB14	NF7OcXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEXhNXRKSzVyPUWuPVcyOzVizszN	M4rGV3NCVkeHUh?=
COLO-829	NWT1NXI6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4n5eWlEPTB;Nj6zN\|M2QSEQvF2=	M3;ES3NCVkeHUh?=
MHH-CALL-2	M3\tcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2O1dmlEPTB;Nj61NVUxQCEQvF2=	NYPOUphKW0GQR1XS
NCI-H1770	NVXIRY9NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlLqTWM2OD14Lk[2PVA1KM7:TR?=	MVTTRW5ITVJ?
ECC4	NYPocXk2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M17ONGlEPTB;Nj64NlE4QSEQvF2=	M{XkUnNCVkeHUh?=
A498	NVnIeWo1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoTmTWM2OD14Lki3NVkzKM7:TR?=	MnXtV2FPT0WU
DMS-79	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mo[zTWM2OD15LkC0OVEzKM7:TR?=	MmHwV2FPT0WU
P30-OHK	NEXnPW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3\BSGlEPTB;Nz6yNVkxPiEQvF2=	MXnTRW5ITVJ?
D-502MG	M1OyZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXTLRWtOUUN3ME23Mlk5OzZizszN	NVf3d29pW0GQR1XS
RCC10RGB	NUfrPWx7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEDwUI9KSzVyPUiuNFYzQCEQvF2=	M3PvPXNCVkeHUh?=
U-698-M	MoLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVzJR\|UxRThwMkmyNlYh\|ryP	M2POT3NCVkeHUh?=
BB49-HNC	NX\SZotrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkfYTWM2OD17LkSyNlY2KM7:TR?=	M3exNnNCVkeHUh?=
ES1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2n6SmlEPTB;OT62PFk2PiEQvF2=	MlTTV2FPT0WU
MFM-223	NEnuWGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MljuTWM2OD1zMD65PVI4KM7:TR?=	NHHBSphUSU6JRWK=
C2BBe1	Ml3JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoDKTWM2OD1zMT6zOVI{KM7:TR?=	MlLCV2FPT0WU
EB2	MkHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUnJR\|UxRTF{Lk[4PFEh\|ryP	M1HwTHNCVkeHUh?=
C8166	MkCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYDFZZZsUUN3ME2xN{45OzB\|IN88US=>	Mof2V2FPT0WU
ES3	NEj6[m5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXrKe25lUUN3ME2xN{46QTd5IN88US=>	M37aUXNCVkeHUh?=
NCI-H1650	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH;6U\|FKSzVyPUG2MlM4PjVizszN	MV\TRW5ITVJ?
Mo-T	NYTpd4RPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFLtbXJKSzVyPUG3MlQxOjlizszN	NHv2dnNUSU6JRWK=
NB7	NUCxcpdLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV7DfJo6UUN3ME2xO{44PDZ5IN88US=>	Mmr0V2FPT0WU
ES7	NWXxVYpmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIfRN4xKSzVyPUG5MlU2ODdizszN	MlfGV2FPT0WU
ES5	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUHJR\|UxRTJzLke2O\|Eh\|ryP	NIn6N5lUSU6JRWK=
MSTO-211H	NF7zOFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm\lTWM2OD1{MT64PFU5KM7:TR?=	MVTTRW5ITVJ?
U-87-MG	M2jYUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHXBPXBKSzVyPUK1MlE6PjZizszN	MW\TRW5ITVJ?
THP-1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MY\JR\|UxRTJ7LkeyNFEh\|ryP	M{PK[nNCVkeHUh?=
NB10	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWjHNlM2UUN3ME2zNE4zPjl2IN88US=>	MmDLV2FPT0WU
NH-12	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYC1N3BUUUN3ME2zN{4zODF5IN88US=>	M1nIXnNCVkeHUh?=
COLO-824	NUjYbZg5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoXzTWM2OD1\|ND6xNFA3KM7:TR?=	NF32Xm1USU6JRWK=
SKM-1	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2PHWmlEPTB;M{euPFQzOiEQvF2=	MlX1V2FPT0WU
NCI-H1838	Mn;sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHjiUVdKSzVyPUO4MlM4QTdizszN	M4HFO3NCVkeHUh?=
RL	NVfoVW9TT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{X3W2lEPTB;M{muNlQ4PyEQvF2=	MYfTRW5ITVJ?
COLO-800	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml7STWM2OD12MD6wO\|c{KM7:TR?=	NVqwWWhiW0GQR1XS
KG-1	NXmzWHpvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoX0TWM2OD12MD64PVU2KM7:TR?=	MmHJV2FPT0WU
TUR	M2jX[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWrJR\|UxRTRzLk[zPVkh\|ryP	MkHKV2FPT0WU
LNCaP-Clone-FGC	NX3ZfVBxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH\VTFRKSzVyPUSxMlkxOTdizszN	MonGV2FPT0WU
NCI-H322M	NX35NWo3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUPDRZdVUUN3ME20Nk42QTh2IN88US=>	NFzQbndUSU6JRWK=
LNCaP	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYnJR\|UxRTlzLkOgcm0>	MkfBNlU2ODVzN{S=
C4-2	NFfjSI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVfJR\|UxRThibl2=	MVmyOVUxPTF5NB?=
JURKAT	MlXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M{HLUlI1KGh?		MmrxTWM2OD12MU[uOlYhdk1?	NVHjO2xPOjR3MUm5PVU>
MOLT-4	NV3JbY1yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M13UblI1KGh?		M2nNVGlEPTB;Mki1N{42KG6P	M1Ps[VI1PTF7OUm1
REH	MonqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MYWyOEBp		M3zUUGlEPTB;Mki3MlY5KG6P	NEDaWHMzPDVzOUm5OS=>
NALM-6	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NWnieHQ6OjRiaB?=		NYno[\|l1UUN3ME2zOFM{OCCwTR?=	MUeyOFUyQTl7NR?=
RS 4;11	NGHvRYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MorjNlQhcA>?		NYqydnhpUUN3ME21NVkvODVibl2=	NE\KS2QzPDVzOUm5OS=>
697	M2PoXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NF\UbIYzPCCq		Mo\FTWM2OD1{MUC3MlEhdk1?	MmPvNlQ2OTl7OUW=
SIL-ALL	M3\ufmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MnXrNlQhcA>?		M3XxPWlEPTB;MUm5Mlc4KG6P	MmL5NlQ2OTl7OUW=
CEM	MkHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NITacI8zPCCq		M1qwWmlEPTB;NUKuNVghdk1?	NEnOV5AzPDVzOUm5OS=>
P12	NEfsOmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHq5clczPCCq		MY\JR\|UxRTN7LkK3JI5O	M1TjWFI1PTF7OUm1
NALM-16	M{TLbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NY\Cd4pYOjRiaB?=		MXvJR\|UxRTl4LkK4JI5O	MVSyOFUyQTl7NR?=
JURKAT	M4fJXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVXGdmtMPDhiaB?=		MXXJR\|UxRTF2Lki0JI5O	NGnLfHczPDVzOUm5OS=>
MOLT-4	NXXmU5NET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MUe0PEBp		MlTiTWM2OD1{Nj62JI5O	NVjLRYhJOjR3MUm5PVU>
REH	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NGLmWIo1QCCq		NU\0cXozUUN3ME20OE44OSCwTR?=	M3\QfFI1PTF7OUm1
NALM-6	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MX:0PEBp		MlmyTWM2OD1{Mz6yOkBvVQ>?	MnewNlQ2OTl7OUW=
RS 4;11	M1\lWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MUG0PEBp		NFTNSmxKSzVyPUG2OE4zQCCwTR?=	NVnrbYtnOjR3MUm5PVU>
697	M3PJVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NFTCV4s1QCCq		M2\Ze2lEPTB;M{C1MlMhdk1?	NWr3[WppOjR3MUm5PVU>
SIL-ALL	NIHnWo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M4fLRVQ5KGh?		M{nrS2lEPTB;N{SuOlIhdk1?	MXiyOFUyQTl7NR?=
CEM	NYnCeoRkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MVu0PEBp		Mn\UTWM2OD1{ND61OUBvVQ>?	Mo\QNlQ2OTl7OUW=
P12	NXu1T4RCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NXrYXVdsPDhiaB?=		MlXhTWM2OD1zOD60OkBvVQ>?	M4TvWFI1PTF7OUm1
NALM-16	NEP4eW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M1WxfVQ5KGh?		Mn7pTWM2OD14Mz6yOEBvVQ>?	NYr5cnZEOjR3MUm5PVU>
JURKAT	MkjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NWLDXW94PzJiaB?=		MVvJR\|UxRTNwNkWgcm0>	MWqyOFUyQTl7NR?=
MOLT-4	NHfp[WlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHnMeZM4OiCq		MYLJR\|UxRTdwM{mgcm0>	MojONlQ2OTl7OUW=
REH	Mn\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFv5XpM4OiCq		M1HCb2lEPTB;MU[uNFEhdk1?	M2rwSlI1PTF7OUm1
NALM-6	M1L5e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NEjMUWk4OiCq		MlnNTWM2OD1zLke4JI5O	MW[yOFUyQTl7NR?=
RS 4;11	M4DXNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NWPkRmJ1PzJiaB?=		NGfkfItKSzVyPUSuN\|ghdk1?	NFLZe5AzPDVzOUm5OS=>
697	M2nHdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NYnFcGIyPzJiaB?=		MVLJR\|UxRTd2LkK4JI5O	NHP5dmwzPDVzOUm5OS=>
SIL-ALL	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NEfG[oQ4OiCq		Ml\XTWM2OD15LkKgcm0>	MmfjNlQ2OTl7OUW=
CEM	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MWC3NkBp		MkjBTWM2OD13LkSyJI5O	MoLpNlQ2OTl7OUW=
P12	NH3L[lVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NF7xSpQ4OiCq		Ml3UTWM2OD14LkO3JI5O	MYKyOFUyQTl7NR?=
NALM-16	M3\1[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXu3NkBp		M2jJOGlEPTB;N{euO\|Mhdk1?	MXiyOFUyQTl7NR?=
Y79	MkP4RZBweHSxc3nzJGF{e2G7	NUDWdpFFOS13MDDuUS=>	MV6xNk8zPCCq	NH\O[YtFVVOR	MVTpcoR2[2WmIHHwc5B1d3OrczD3bIlkcCClYX6gZoUh\W6qYX7j[YQh[nliSGS=	M1GwfFI1OzZ4Nk[1
WER-Rb-1	NHXI[YdCeG:ydH;zbZMhSXO\|YYm=	NXnXNJhWOS13MDDuUS=>	M3\DTVEzNzJ2IHi=	M{nzc2ROW09?	MXvpcoR2[2WmIHHwc5B1d3OrczD3bIlkcCClYX6gZoUh\W6qYX7j[YQh[nliSGS=	MmHhNlQ{PjZ4NkW=
G7	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYnJR\|UxRTNwMzDuUS=>	M3zIRVI1OjB2N{Oz
G166	NIfVVHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUTJR\|UxRTdwMDDuUS=>	M2e5RlI1OjB2N{Oz
CB660	MnPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Moj2TWM2OD14LkSgcm0>	NEjMOmIzPDJyNEezNy=>
CB1117	NUPxZWFHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHLuZ\|ZKSzVyPUG1MlYhdk1?	NHy1e2MzPDJyNEezNy=>
KB-3-1	MmnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEPZTGNKSzVyPUGuOFghyrFiMD61N{BvVQ>?	M1u1eVI{QTZ{NES1
KB-8-5-11	M3izSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVvuPGt1UUN3ME21MlAyKMLzIEKuNFEhdk1?	MkT6NlM6PjJ2NEW=
KB-C-1	MkDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3y1[WlEPTB;MU[uO\|YhyrFiND61NUBvVQ>?	MoDONlM6PjJ2NEW=
KB-V-1	M4nxXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUT6b4FvUUN3ME2yPFEvOjRiwsGgN\|EvPTdibl2=	NH7QOZAzOzl4MkS0OS=>
OVCAR-8	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXLPemg2UUN3ME23MlE6KMLzIEOuOlAhdk1?	MkjsNlM6PjJ2NEW=
NCI-ADR-RES	NWfl[2VoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3z5fmlEPTB;MUK3N{4{OCEEsTCxPVEvOjBibl2=	Mm[yNlM6PjJ2NEW=
MCF7	MkHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M13rO2lEPTB;NT6xNUDDuSBzLkS3JI5O	NGnnWYYzOzl4MkS0OS=>
MCF7-FLV1000	M33KbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVTJR\|UxRTN7Mz6xPEDDuSB5ND64N{BvVQ>?	MnfLNlM6PjJ2NEW=
S1	NHjKUGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2HyO2lEPTB;MkSuN\|AhyrFiND63OUBvVQ>?	NXL5R2FwOjN7NkK0OFU>
S1-M1-80	NGXHNY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NULBXHZTUUN3ME2yOlEvODZiwsGgOFgvOjVibl2=	M1y2fVI{QTZ{NES1
CORL-23/P	NV;TblBST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXi0PHlVUUN3ME20MlM5KMLzIEGuNlUhdk1?	M3;hflI{QTZ{NES1
CORL-23/R	Mk\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV3JR\|UxRTVwMU[gxtEhOS56MzDuUS=>	NGLSPZYzOzl4MkS0OS=>
NIH3T3	NVWwZ2F4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn\0TWM2OD12MD62NEDDuSB2Lkm3JI5O	M3OzdFI{QTZ{NES1
NIH3T3-G185	NWDpfWxOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUnJR\|UxRTJ2MUOuOFAhyrFiNEKzMlY3KG6P	NYrXcY9POjN7NkK0OFU>
pcDNA-HEK293	NXHJXYRuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3PMTGlEPTB;Mj63OUDDuSByLk[3JI5O	MmDMNlM6PjJ2NEW=
MDR19-HEK293	M17Idmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUXJR\|UxRTh3LkWwJOKyKDF\|Lk[3JI5O	NVXMTFZsOjN7NkK0OFU>
R482-HEK293	MkjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUKyUnRoUUN3ME2yOU46PyEEsTC0Mlk2KG6P	Mo\zNlM6PjJ2NEW=
MRP1-HEK293	MmK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXfWeGJCUUN3ME2yMlk6KMLzIEGuOFkhdk1?	MUmyN\|k3OjR2NR?=
SF188	MonsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1PH[VExNTFyMDDuUS=>	MonxNlQuQTZiaB?=	NYjaXFFJTE2VTx?=	NETsRoxqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CClb37j[Y51emG2aX;uMUBl\XCnZHXueEBu[W6wZYK=	M2D2elI{QDh5NkS1
T98G	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXzRVoFFOTBvMUCwJI5O	NYrQfWZMOjRvOU[gbC=>	NEDzdY1FVVOR	MnzYbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iY3;uZ4VvfHKjdHnvck0h\GWyZXTlcpQhdWGwbnXy	NXfkXJBrOjN6OEe2OFU>
DU145	NIO5RXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			Mnq5SG1UVw>?	NVXlNWZtUUN3MPMIwFYxKG6P	NU\JeWd{OjN6OES0Nlg>
LNCaP	NUjOfVZbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MkPNSG1UVw>?	MnH4TWM2OOLKvEe1JI5O	MW[yN\|g5PDR{OB?=
PC3	NIH1XIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MkjRSG1UVw>?	NXfNVZJ{UUN3MPMIwFE4PSCwTR?=	M2XlZ\|I{QDh2NEK4
RT4	NXWzSpRZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlHuTWM2OD1{Nz6yNUBvVQ>?	NIPBNIMzOzd7Mk[zPS=>
5637	NVzpRoZiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkKxTWM2OD12NT60O{BvVQ>?	NUS2WWdDOjN5OUK2N\|k>
T24	Mn7lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MljTTWM2OD15OT6xNkBvVQ>?	MknUNlM4QTJ4M{m=
MCF7	MnviSpVv[3Srb36gRZN{[Xl?	NID1XVkyODBibl2=	M3HNSFEhcA>?	NWDm[Ig6TE2VTx?=	NWjtRlM4emWmdXPld{B1cGViaX7keYN1cW:wIH;mxsBIemWkMT\|CpHNoczFuwrDQd\|ItyqCVZYLwbY5iOyxiYX7kxsBYcXOyMh?=	MoTRNlM4PzB{NES=
KB-V1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFjGUXRKSzVyPUOuPVIh\|ryP	MYeyN\|U6OzF7Nh?=
Hec50co	MmixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlXQTWM2OD13IH7N	MoG3NlMyPDZ4OEe=
MDA-MB-468	MlXIRZBweHSxc3nzJGF{e2G7	NIHrWXIyNzVxMUCgcm0>	Ml\DNlQwPDhxN{KgbC=>	Mom3SG1UVw>?	Mn23bY5lfWOnczDhdI9xfG:\|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NFH3WHQzOzF2NEK5OC=>
MCF10A	MVjBdI9xfG:\|aYOgRZN{[Xl?	M3HablEwPS9zMDDuUS=>	NF7IZZYzPC92OD:3NkBp	M3rCbGROW09?	MX7pcoR2[2W\|IHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	MnW1NlMyPDR{OUS=
Huh-7	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHnyWZkyNzFyL{GwNE8yODByIH7N	NVX2ZZdCPDhiaB?=		Ml;3[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBld3OnLXTldIVv\GWwdHz5	NI\hSoEzOjd2NUW4Oy=>
Daoy	MmP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGK1R2cyNjh5NT2yOFAhdk1?	NIToeVU4OiCq	NYPHN3pSTE2VTx?=	NHWxd3FKSzVyPUWgcm0>	NGHU[4IzOjN7MEK3PS=>
ONS-76	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoDaNU45PzVvMkSwJI5O	MnXkO\|IhcA>?	MV3EUXNQ	MmHaTWM2OD15LkWgcm0>	MoP5NlI{QTB{N{m=
SUM 149	NVPBWFdUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYTTUG1MOC1zMECgcm0>	M2rMWlczKGh?		MnTzbY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnHy	MlTpNlI{ODl7M{m=
MDA-MB-231	M{TSXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3WwPFAuOTByIH7N	NFzTdFQ4OiCq		MnfwbY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnHy	NWT4OY1QOjJ\|MEm5N\|k>
HR5	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmjaNE0yODBibl2=	NEXncVg4OiCq		NEXKPGJqdmirYnn0d{B1cGViY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7uZZI>	Ml7sNlI{ODl7M{m=
BT-474-M1	NGnTPIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGHlc4QxNTFyMDDuUS=>	MVW3NkBp		MYXpcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wYYK=	MkHXNlI{ODl7M{m=
AU565	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYLNPYQ2OC1zMECgcm0>	M1zBXVczKGh?		NXftWXRGcW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoFz	NWDmTVZCOjJ\|MEm5N\|k>
T47D	M13qUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUnOV4RyOC1zMECgcm0>	M37TWVczKGh?		Ml\UbY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnHy	MV[yNlMxQTl\|OR?=
MCF7	NHXM[2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV6wMVExOCCwTR?=	M1OzTlczKGh?		NVPjXnlkcW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoFz	M2[3cFIzOzB7OUO5
HCT116p53(+/+)	M1jkW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4XXe\|ExNTFyMECgcm0>	MkX4NlQwPDhiaB?=		MkPibY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJINwdXCuZYTlcJkh[XRiMkWgcm0>	NFnYO3QzOjJ4MkG3NS=>
HCT116p53(-/-)	NVzHfoExT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXrLWHhpOTBvMUCwNEBvVQ>?	NVX6NHJWOjRxNEigbC=>		M3TCXYlvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckBkd22ybHX0[Yx6KGG2IEK1JI5O	M4\MOVIzOjZ{MUex
HeLa	M{i2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlXBNVAuOTByIH7N	M4W0S\|Q5KGh?	MWjEUXNQ	MkTOTWM2OD13Mj65JI5O	M17rWFIzODhyMkO1
HeLa	NYPwdFVKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoLhNVAuOTByIH7N	NV3ZN4RsPzJiaB?=	M1:yPWROW09?	M1Lic2lEPTB;NUCuOUBvVQ>?	MmCxNlIxQDB{M{W=
GBC	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NWTvN4dxPzJiaB?=		Ml3UTWM2OD1zND63PEBvVQ>?	NHnaPZozOTl4NUezPS=>
GB-CL-1	MlyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1nJO\|czKGh?		Ml3oTWM2OD13LkKyJI5O	MkjENlE6PjV5M{m=
Mz-ChA-2	M3:1UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2\y[FczKGh?		MUDJR\|UxRTNwM{Ggcm0>	MVuyNVk3PTd\|OR?=
TGBC1-TKB	M4jofWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NGXUcZoyPDRiaB?=		MUjJR\|UxRTZwN{Kgcm0>	M2PONVIyQTZ3N{O5
Wittier	NGnhVnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MYO3NkBp		MX\JR\|UxRTNwMk[gcm0>	MmDrNlE6PjV5M{m=
H-1	MkXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MXK3NkBp		MkTFTWM2OD17LkW0JI5O	MmHtNlE6PjV5M{m=
HuH-28	NEjY[FdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NF23T284OiCq		NEHhRVFKSzVyPUGxMlE6KG6P	NEPyeVEzOTl4NUezPS=>
NEC	NVexRoJWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NVrUbnl5PzJiaB?=		NXnyeI02UUN3ME25Mlk5KG6P	M3e2NFIyQTZ3N{O5
REB	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NF\jS5k4OiCq		NIOyfmZKSzVyPUGzMlUyKG6P	NX7LdYlXOjF7NkW3N\|k>
CC-LP-1	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NUHKN\|liPzJiaB?=		M{fQUWlEPTB;NT64OEBvVQ>?	NXzvU4lnOjF7NkW3N\|k>
CC-SW-1	NFu5T3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NIX6[pU4OiCq		NH\5WGVKSzVyPUmuOVUhdk1?	MViyNVk3PTd\|OR?=
EGI-1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3y2R\|czKGh?		MV\JR\|UxRTFyLkeyJI5O	NHXrNFczOTl4NUezPS=>
Sk-ChA-1	M1\sUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MmDlO\|IhcA>?		MoP5TWM2OD1zNz6yJI5O	NGfGSm8zOTl4NUezPS=>
TFK-1	NV7xbWZrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MUm3NkBp		MYHJR\|UxRTF\|LkS1JI5O	MoTiNlE6PjV5M{m=
786-O	M4r1VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIfGV2k2NThyIH7N	NWXKPFU{QTZiaB?=	MVvIR4w>	NVnjeYVUe3WycILld5NmeyC2aHWgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meiC5aYToJGlEPTEEoI\hcJVmeyCxZjCyJJRwKDJyIH7N	M1GzUFIyPjR{M{e0
A498	NUP6d\|JnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{PQWlUuQDBibl2=	MYi5OkBp	MmWwTGNt	MXPzeZBxemW\|c3XzJJRp\SCycn;sbYZmemG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJJdqfGhiSVO1NOKhfmGudXXzJI9nKDJidH:gNlAhdk1?	MYSyNVY1OjN5NB?=
ACHN	NUjQV5Y{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYPqV2xuPS16MDDuUS=>	Mn7yPVYhcA>?	MYfIR4w>	M2TOTZN2eHC{ZYPz[ZMhfGinIIDyc4xq\mW{YYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIhf2m2aDDJR\|UxyqC4YXz1[ZMhd2ZiMjD0c{AzOCCwTR?=	MljHNlE3PDJ\|N{S=
Caki-1	NI\MO4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlLaOU05OCCwTR?=	MWe5OkBp	NFPibVFJS2x?	NFqzR\|R{fXCycnXzd4V{KHSqZTDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzKHerdHigTWM2OMLidnHseYV{KG:oIEKgeI8hOjBibl2=	NXO2UGlGOjF4NEKzO\|Q>
SN12C	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml7XOU05OCCwTR?=	NYXlNmwxQTZiaB?=	NETHSlhJS2x?	MWPzeZBxemW\|c3XzJJRp\SCycn;sbYZmemG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJJdqfGhiSVO1NOKhfmGudXXzJI9nKDJidH:gNlAhdk1?	M3jpW\|IyPjR{M{e0
HMC-1.1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlzlNU0yODByIH7N	MXm3NkBp		NVGyTW9qcW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6n	NYLWSoRkOjF{NEKxPFk>
HMC-1.2	NXTmTmF2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXqxMVExODBibl2=	NVG0bm43PzJiaB?=		M{HNcolvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\Q>?	MojONlEzPDJzOEm=
C2	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2raNFEuOTByMDDuUS=>	NXHJWmQ3PzJiaB?=		MU\pcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoU>	MXyyNVI1OjF6OR?=
CHP-212	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV6xMVEzPSCwTR?=	NIrN[3QzPC1zMkCgbC=>		M4naVYlvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnW=	Ml;GNlEyPjl{NEK=
IMR-32	MkXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4PjN\|EuOTJ3IH7N	NF\iN\|IzPC1zMkCgbC=>		NEDF[\|lqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHnuJIJwfGhidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7l	NWjMNVR3OjFzNkmyOFI>
Kelly	MmPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3v3elEuOTJ3IH7N	NFqz[FAzPC1zMkCgbC=>		NX\0Z45[cW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbjDpckBjd3SqIITpcYUuKGGwZDDkc5NmNWSncHXu[IVvfCCvYX7u[S=>	MmnRNlEyPjl{NEK=
SH-EP	MmLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYGxMVEzPSCwTR?=	NEXub4czPC1zMkCgbC=>		NYfKOIhtcW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbjDpckBjd3SqIITpcYUuKGGwZDDkc5NmNWSncHXu[IVvfCCvYX7u[S=>	MWWyNVE3QTJ2Mh?=
SH-SY5Y	MnHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXyxMVEzPSCwTR?=	M1fI[VI1NTF{MDDo		M4fFbIlvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnW=	NIrxcGkzOTF4OUK0Ni=>
SK-N-AS	M3;1SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXexMVEzPSCwTR?=	M3jm[lI1NTF{MDDo		NG\RW5dqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHnuJIJwfGhidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7l	NYPjWHRXOjFzNkmyOFI>
SK-N-BE	MnvtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlfINU0yOjVibl2=	M4\1PVI1NTF{MDDo		M1TPN4lvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnW=	M{GxU\|IyOTZ7MkSy
KG1	NGXte29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIflS4kyNzFyL{GwNEBvVQ>?	MV63NkBp	NFnvdW9FVVOR	MVjpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6n	Mkn2NVk1PTh\|NUi=
U937	M{fj[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnLpNU8yOC9zMECgcm0>	MYe3NkBp	MmTUSG1UVw>?	MX3pcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6n	Ml3SNVk1PTh\|NUi=
CAL62	NXTETlJpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NULKSGlpOC5zLUGwNEBvVQ>?	MonqO\|IhcA>?	NFnYR5hFVVOR	MlvZSWM2OD1zLkSgcm0>	Mm\JNVkzOjN3NUO=
OCUT-1	NYLQfYJTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV7wZ\|RIOC5zLUGwNEBvVQ>?	M{HRflczKGh?	MYnEUXNQ	M{XBSmVEPTB;Mj6zJI5O	M1\ydlE6OjJ\|NUWz
8505C	M1TW[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX3Cd497OC5zLUGwNEBvVQ>?	NYnLS4VxPzJiaB?=	NVy0bHZITE2VTx?=	MnHUSWM2OD1\|LkKgcm0>	MXyxPVIzOzV3Mx?=
ACT-1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NELY[IUxNjFvMUCwJI5O	MXe3NkBp	MWnEUXNQ	NHPaRWxGSzVyPUWuOEBvVQ>?	MoW0NVkzOjN3NUO=
SW1736	NE\BeVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIn4VHkxNjFvMUCwJI5O	NF:3XnU4OiCq	M4HYSGROW09?	NVW4PVVQTUN3ME21MlYhdk1?	MYGxPVIzOzV3Mx?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pro-caspase-8 / cleaved caspase-8 / cleaved caspase-3 / cleaved caspase-9; PubMed: 27699933 Cancer Sci PLKi‐induced caspase activation. HeLa cells were treated with BI 2536 (10 nmol/L), BI 6727 (68 nmol/L), or GSK461364 (11 nmol/L), and HCT 116 cells were treated with BI 2536 (20 nmol/L), BI 6727 (70 nmol/L), or GSK461364 (12 nmol/L) for 48 h. The levels of cleaved caspase (CASP)‐3, ‐8, and ‐9 were examined by Western blot analysis. p-HH3 / PARP / Myc / p-Myc; PubMed: 24771642 Clin Cancer Res Western blotting showing more mitotic arrested (shown by phospho-histone H3) and apoptotic (shown by PARP) cells as well as lower MYC levels in LNCaP-Pim1 cells after BI 2536 treatment compared with LNCaP-Neo cells. The difference is obvious at lower dose of BI 2536 (10 nM). Both total MYC expression and phosphor-MYC levels were lower in Pim1 cells than Neo cells after BI 2536 treatment. pMEK / MEK / pERK / ERK / pRSK1 / RSK1; PubMed: 28430578 Oncotarget (A) and (B) Western blot analysis of the expression and activation of components of the MEK-ERK-RSK1 pathway in MKN45 and MKN74 cancer cells treated with BI 2536 and BI 6727 for 24 and 48 hours, respectively. pPlk1 / Plk1 / pMyt1; PubMed: 28430578 Oncotarget (A) and (B) Western blot analysis of the expression and phosphorylation of Plk1, and phosphorylation of Myt1 in the CSC-like and cancer cells after treatment with BI 2536 and BI 6727 for 24 and 48 hours, respectively. Aurora B / pAurora B / pAurora C / pH3 / Cyclin B1 / Securin / pBcl-XL / MPM2; PubMed: 25169932 Mol Oncol Western blot analysis of cells treated for 24 h with the indicated inhibitor concentrations. Cell lysates were immunoblotted for Plk1, Phospho-Aurora B (T232)/Aurora C (T198), Aurora B, histone H3 phosphorylated at S10 (pH3), Cdk1, Cyclin B1, Securin, Phospho-Bcl-XL, Induced myeloid leukemia cell differentiation protein Mcl-1, MPM-2 and β-Actin. Left (Hela cells); Right (HUVEC)	27699933 24771642 28430578 25169932
Immunofluorescence	p-H2AX / propidium iodide; PubMed: 22309939 Breast Cancer Res Apoptotic images of the cells after BI 2536 treatment, as revealed by HCS (high-content screening) instrument (×10) with phospho-H2AX antibody or PI (propidium iodide) intake. Pericentrin / α-tubulin; PubMed: 21772266 Nat Commun MEFs were labelled using Plk1, pericentrin and α-tubulin antibodies and 4,6-diamidino-2-phenylindole for the analysis by immunofluorescence microscopy. Representative examples of BI 2536-treated and control MEFs are depicted. Scale bar, 5 μm.	22309939 21772266
Growth inhibition assay	Cell viability; PubMed: 21772266 Nat Commun Proliferative activity of MEFs at different BI 2536 concentrations (25–250 nM; means±s.d., n=3, for each concentration). P<0.05, P<0.01, **P<0.001, Student's t-test, unpaired and two-tailed.	21772266

In vivo

BI 2536 given i.v. once or twice per week is highly efficacious in diverse xenograft models with acceptable tolerability by inhibiting cell proliferation through a mitotic arrest, and subsequently induction of tumor-cell death. Administration of BI 2536 at 50 mg/kg once or twice per week significantly inhibits growth of HCT 116 xenografts with T/C of 15% and 0.3%, respectively. BI 2536 treatment twice-weekly also leads to excellent tumor-growth in BxPC-3 and A549 models with T/C of 5% and 14%, respectively. ^[1]

Protocol

Kinase Assay:^[1]	- Collapse Plk1 in vitro kinase assay: Recombinant human Plk1 (residues 1-603) is expressed as N-terminal, GST-tagged fusion protein with a baculoviral expression system and purified by affinity chromatography with Glutathione-agarose. Enzyme activity assays for Plk1 are performed in the presence of serially diluted BI 2536 with 20 ng of recombinant kinase and 10 μg casein from bovine milk as the substrate. Kinase reactions are performed in a final volume of 60 μL for 45 minutes at 30 °C (15 mM MgCl₂, 25 mM MOPS [pH 7.0], 1 mM DTT, 1% DMSO, 7.5 mM ATP, 0.3 μCi γ-³³P-ATP). Reactions are terminated by the addition of 125 μL of ice-cold 5% TCA. After transfer of the precipitates to Multi-Screen mixed ester cellulose filter plates, plates are washed with 1% TCA and quantified radiometrically. Dose-response curve is used for calculating IC50 value.
Cell Research:^[1]	- Collapse Cell lines: HeLa, A43, SKOV-3, HT-29, K562, A549, Saos-2, MCF7, HCT116, COLO 205, Hep G2, Raji and PC-3 cells, etc. Concentrations: Dissolved in DMSO, final concentrations ~1 μM Incubation Time: 24 and 72 hours Method: Cells are exposed to various concentrations of BI 2536 for 24, and 72 hours. Cell growth is assessed by the measurement of Alamar Blue dye conversion in a fluorescence spectrophotometer. For determining the DNA content of the cultures, cell suspensions are fixed in 80% ethanol, treated for 5 minutes with 0.25% Triton X-100 in PBS, and incubated with 0.1% RNase and 10 μg/mL propidium iodide (PI) in PBS for 20 minutes at RT. Cell-cycle profiles are determined by flow cytometric analysis. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: Female BomTac:NMRI-Foxn1^nu mice injected subcutaneously with HCT 116, NCI-H460, or A549 cells Dosages: ~50 mg/kg Administration: Injection i.v. once or twice per week (Only for Reference)

References

Solubility (25°C)

In vitro	Ethanol	100 mg/mL (191.69 mM)
	DMSO	21 mg/mL (40.25 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 30% PEG 400+0.5% Tween 80+5% Propylene glycol For best results, use promptly after mixing.	15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download BI 2536 SDF

Molecular Weight	521.66
Formula	C₂₈H₃₉N₇O₃
CAS No.	755038-02-9
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A
Smiles	CCC1N(C2CCCC2)C3=NC(=NC=C3N(C)C1=O)NC4=CC=C(C=C4OC)C(=O)NC5CCN(C)CC5

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-05-15)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02215044	Terminated	Drug: BI 2536 intravenous\|Drug: Gemcitabine intravenous	Pancreatic Neoplasms	Boehringer Ingelheim	June 2007	Phase 1
NCT02211833	Completed	Drug: BI 2536\|Drug: Pemetrexed	Carcinoma Non-Small-Cell Lung	Boehringer Ingelheim	October 2006	Phase 1
NCT00701766	Completed	Drug: BI 2536	Leukemia Myeloid Acute	Boehringer Ingelheim	October 2006	Phase 2
NCT00706498	Completed	Drug: BI 2536	Prostatic Neoplasms	Boehringer Ingelheim	September 2006	Phase 2
NCT00376623	Completed	Drug: BI 2536	Carcinoma Non-Small-Cell Lung	Boehringer Ingelheim	July 2006	Phase 2
NCT02211872	Completed	Drug: BI 2536 BS intravenous	Neoplasms	Boehringer Ingelheim	August 2004	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
We need to use BI 2536 in preclinical studies using mice, how to formulate the inhibitor for this in vivo study?
Answer:
For in vivo study, DMSO should not be more than 5% because the toxicity. You can formulated BI2536 in hydrochloric acid (0.1 N), and diluted with 0.9% NaCl for animal study according to the reference :( Supplemental Data) http://linkinghub.elsevier.com/retrieve/pii/S0960-9822(06)02671-6

PLK Signaling Pathway Map

PLK Inhibitors with Unique Features

Selective Plk Inhibitors

GSK461364 : Plk1-selective, K_i=2.2 nM.
Plk Inhibitor in Clinical Trial

Rigosertib (ON-01910) : Phase III for Myelo Dysplastic Syndrome (MDS).
Newest Plk Inhibitor

Ro3280 ^New : Potent, highly selective inhibitor of Polo-like kinase 1 (PLK1) with IC50 of 3 nM.
Calssic Plk Inhibitor

Volasertib (BI 6727) : Highly potent Plk1 inhibitor with IC50 of 0.87 nM and in phase II trials.

Related PLK Products

SBE 13 HCl ^New

SBE 13 HCl is a potent and selective PLK1 inhibitor with IC50 of 200 pM, >4000-fold selectivity over Aurora A kinase, Plk2 and Plk3.
Ro-3306 ^New

RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with K_i of 20 nM, >15-fold selectivity against a diverse panel of human kinases.
CCG-1423 ^New

CCG-1423 is a specific RhoA pathway inhibitor, which inhibits SRF-mediated transcription.
Rigosertib (ON-01910)

Rigosertib (ON-01910) is a non-ATP-competitive inhibitor of PLK1 with IC50 of 9 nM in a cell-free assay. It shows 30-fold greater selectivity against Plk2 and no activity to Plk3. Phase 3.
HMN-214

HMN-214 is a prodrug of HMN-176, which alters the cellular spatial orientation of Plk1.
GSK461364

GSK461364 inhibits purified Plk1 with K_i of 2.2 nM in a cell-free assay. It is more than 1000-fold selective against Plk2/3. Phase 1.

Features:Demonstrates >390-fold selectivity for Plk1 relative to Plk2 and Plk3.
Volasertib (BI 6727)

Volasertib (BI 6727) is a highly potent Plk1 inhibitor with IC50 of 0.87 nM in a cell-free assay. It shows 6- and 65-fold greater selectivity against Plk2 and Plk3. Phase 3.

Features:A high volume of distribution, indicating good tissue penetration, and a long terminal half-life.
MLN0905

MLN0905 is a potent inhibitor of PLK1 with IC50 of 2 nM.
Ro3280

RO3280 is a potent, highly selective inhibitor of Polo-like kinase 1 (PLK1) with IC50 of 3 nM.

Features:A selective PLK1 inhibitor. Demonstrates greater potency than BI2536. Potential use in nasopharyngeal carcinomas.
onvansertib (NMS-P937)

onvansertib (NMS-P937) is an orally available, selective Polo-like Kinase 1 (PLK1) inhibitor with IC50 of 2 nM, 5000-fold selectivity over PLK2/PLK3. Phase 1.

Choose Your Country or Region

By Signaling Pathways

By product type

BI 2536